 CAMBRIDGE, Mass. SALISBURY, England--BUSINESS WIRE--- KALV EAACI2021--KalVista Pharmaceuticals, Inc. NASDAQ: KALV, a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced data presented for its oral drug candidates at the European Academy of Allergy and Clinical Immunology EAACI Congress. Data presentations include a late-breaking poster for the Phase 2 data for KVD900, KalVistas lead drug program for ora 